Proteomics Market Size, Share & Trends Analysis By Technology, By Reagent, By Software & Service, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Description

The global proteomics market is projected to be worth USD 92.55 billion by 2030

According to SPER Market Research, the proteomics market is estimated to reach USD 92.55 billion by 2030 with a CAGR of 15.2%. The rising prevalence of infectious diseases has increased the demand for the study of proteins and gene sequencing. This study can help in developing novel treatments against viral diseases, cancer, and other genetic disorders.

Impact of COVID-19 on the proteomics Market

The COVID-19 pandemic has increased the focus on decoding 3d structures of SARS-CoV-2 proteins. In order to understand therapies against COVID-19, protein crystallization techniques have played a significant role to understand virus proteins and specific sites. This has impacted the proteomics market in positively and the marker has grown further.

Scope of the report:

Market size available for years: 2019-2030
Base year considered: 2021
Forecast period: 2022-2030

Segments covered By Technology, By Reagents, By Software & Services, By Application, By End-User.

Geographies covered: North America, Europe, APAC, Latin America and the Middle East & Africa.

Companies Covered:

Agilent Technologies, Inc., Applied Biomics, Inc., Biognosys AG, Biomax Informatics AG, Bioproximity, Bio-Rad Laboratories, Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, Eurofins Scientific, Fios Genomics Ltd., GE Healthcare, GENEWIZ, HORIBA, Ltd., Illumina, Inc., Integrated Proteomics Applications, Luminex Corporation, Merck KGaA, MRM Proteomics Inc., MS Bioworks LLC, PerkinElmer Inc., Poochon Scientific, LLC, Promega Corporation, Proteome Factory AG, QIAGEN Bioinformatics

Driver: Rising incidence of cancer and genetic disorders

The incidence of cancer and geriatric disorders is rising creating an urgent need for better therapeutics. The recent discoveries around the sequencing of the human genome are helping in developing novel treatments by evaluating gene expression at the proteome level. The extraction of biological information in diseased patients can help in the development of novel treatments and thus can drive the proteomics market

Opportunity: Rising demand for nanoproteomics

Nanotechnology is gaining popularity in the plethora of applications in various industries. In proteomics, nanotechnology can be utilized to develop phosphoproteomics, nanostructured surfaces for protein separation, and detection techniques for biomarkers protein. The growth of nanoproteomics technology is providing growth opportunities to the proteomics market

Challenge: High cost of equipment

The research activities involved in proteomics & genomics involve highly expensive instruments and reagents. The cost of installation along with maintenance charges and indirect costs makes it very challenging for developing countries to adopt these technologies

Proteomics Market by Technology:

Based on technology, the market has been segmented into Spectroscopy (Mass Spectroscopy, NMR Spectroscopy, CD Spectroscopy), Chromatography (HPLC, Ion Chromatography, Affinity Chromatography, Supercritical Fluid Chromatography), Electrophoresis (Gel Electrophoresis, Capillary Electrophoresis), Protein Microarrays (Biochips [Lab-on-Chips, Protein Chips], Micrparray Instruments [Integrated Systems, Microarray Scanners, Arrayers]), X-Ray Crystallography, Surface Plasmon Resonance, Protein Fractionation

Proteomics Market by Reagents:

Based on reagents, the market is segmented into Immunoassay Reagents, Spectroscopy Reagents, Chromatography Reagents, Protein Microarray Reagents, X-Ray Crystallography Reagents, Electrophoresis Reagents, Protein Fractionation Reagents

Proteomics Market by Software & Services:

Based on software & services, the market is segmented into Core Proteomics Services (Protein Identification Services, Protein Characterization Services, Quantitative Proteomic Services, Protein Purification Services, Protein Sequencing Services, Custom Assay Services), Bioinformatics Software & Services (Bioinformatics Software, Bioinformatics Tools, Bioinformatics Databases)

Proteomics Market by Application:

Based on application, the market is segmented into Clinical Diagnostics (Cancer, Infectious Diseases, Diabetes, Neurological Disorders, Immune Diseases, Cardiovascular Diseases, and Other Clinical Diagnostic Applications), Drug Discovery (Target Discovery, Lead Identification, Lead Optimization, Preclinical Studies), Other Application

Proteomics Market by End User:

Based on end-users, the market is segmented into Hospitals, Clinical Laboratories, Pharmaceutical Companies, Academic Research Laboratories, and Other End Users.

Pharmaceutical & Biotechnological companies have the largest share of this market by the end-user due to rising public & private funding for proteomics & genomics research activities and rising outsourcing of research activities to CRO services associated with pharmaceutical companies

Proteomics Market by Region:

North America owns the largest share of this market owing to rising investments & funding, rising preference for high-quality research, focus on reproducibility in research, raising awareness for personalized medicines, and presence of leading players in this market

Product Code: BIOT2225

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary data
- 2.1.2. Primary data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity, and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impact on the Proteomics Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL analysis
- 5.2.1. Political landscape
- 5.2.2. Economic landscape
- 5.2.3. Social landscape
- 5.2.4. Technological landscape
- 5.2.5. Environmental landscape
- 5.2.6. Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of Buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat map analysis

6. Global Proteomics Market, By Technology, 2019-2030 (USD Million)

6.1. Spectroscopy
- 6.1.1. Mass Spectroscopy
- 6.1.2. NMR Spectroscopy
- 6.1.3. CD Spectroscopy
6.2. Chromatography
- 6.2.1. HPLC
- 6.2.2. Ion Chromatography
- 6.2.3. Affinity Chromatography
- 6.2.4. Supercritical Fluid Chromatography
6.3. Electrophoresis
- 6.3.1. Gel Electrophoresis
- 6.3.2. Capillary Electrophoresis
6.4. Protein Microarrays
- 6.4.1. Biochips
  - 6.4.1.1. Lab-on-Chips
  - 6.4.1.2. Protein Chips
- 6.4.2. Micrparray Instruments
  - 6.4.2.1. Integrated Systems
  - 6.4.2.2. Microarray Scanners
  - 6.4.2.3. Arrayers
6.5. X-Ray Crystallography
6.6. Surface Plasmon Resonance
6.7. Protein Fractionation

7. Global Proteomics Market, By Reagents, 2019-2030 (USD Million)

7.1. Immunoassay Reagents
7.2. Spectroscopy Reagents
7.3. Chromatography Reagents
7.4. Protein Microarray Reagents
7.5. X-Ray Crystallography Reagents
7.6. Electrophoresis Reagents
7.7. Protein Fractionation Reagents

8. Global Proteomics Market, By Software & Services, 2019-2030 (USD Million)

8.1. Core Proteomics Services
- 8.1.1. Protein Identification Services
- 8.1.2. Protein Characterization Services
- 8.1.3. Quantitative Proteomic Services
- 8.1.4. Protein Purification Services
- 8.1.5. Protein Sequencing Services
- 8.1.6. Custom Assay Services
8.2. Bioinformatics Software & Services
- 8.2.1. Bioinformatics Software
- 8.2.2. Bioinformatics Tools
- 8.2.3. Bioinformatics Databases

9. Global Proteomics Market, By Application, 2019-2030 (USD Million)

9.1. Clinical Diagnostics
- 9.1.1. Cancer
- 9.1.2. Infectious Diseases
- 9.1.3. Diabetes
- 9.1.4. Neurological Disorders
- 9.1.5. Immune Diseases
- 9.1.6. Cardiovascular Diseases
- 9.1.7. Other Clinical Diagnostic Applications
9.2. Drug Discovery
- 9.2.1. Target Discovery
- 9.2.2. Lead Identification
- 9.2.3. Lead Optimization
- 9.2.4. Preclinical Studies
9.3. Other Application

10. Global Proteomics Market, By End User, 2019-2030 (USD Million)

10.1. Hospitals
10.2. Clinical Laboratories
10.3. Pharmaceutical Companies
10.4. Academic Research Laboratories
10.5. Other End Users

11. Global Proteomics Market, By Region, 2019-2030 (USD Million)

11.1. North America
- 11.1.1. United States
- 11.1.2. Canada
- 11.1.3. Mexico
11.2. Europe
- 11.2.1. Germany
- 11.2.2. United Kingdom
- 11.2.3. France
- 11.2.4. Italy
- 11.2.5. Spain
- 11.2.6. Rest of Europe
11.3. Asia-Pacific
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Australia
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. South America
- 11.4.1. Brazil
- 11.4.2. Argentina
- 11.4.3. Rest of South America
11.5. Middle East & Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Rest of Middle East & Africa

12. Company Profiles

12.1. Agilent Technologies, Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Applied Biomics, Inc.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Biognosys AG
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Biomax Informatics AG
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Bioproximity
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Bio-Rad Laboratories, Inc.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Bruker Corporation
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Creative Proteomics
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Danaher Corporation
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Eurofins Scientific
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Fios Genomics Ltd.
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
12.12. GE Healthcare
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
12.13. GENEWIZ
- 12.13.1. Company details
- 12.13.2. Financial outlook
- 12.13.3. Product summary
- 12.13.4. Recent developments
12.14. HORIBA, Ltd.
- 12.14.1. Company details
- 12.14.2. Financial outlook
- 12.14.3. Product summary
- 12.14.4. Recent developments
12.15. Illumina, Inc.
- 12.15.1. Company details
- 12.15.2. Financial outlook
- 12.15.3. Product summary
- 12.15.4. Recent developments
12.16. Integrated Proteomics Applications
- 12.16.1. Company details
- 12.16.2. Financial outlook
- 12.16.3. Product summary
- 12.16.4. Recent developments
12.17. Luminex Corporation
- 12.17.1. Company details
- 12.17.2. Financial outlook
- 12.17.3. Product summary
- 12.17.4. Recent developments
12.18. Merck KGaA
- 12.18.1. Company details
- 12.18.2. Financial outlook
- 12.18.3. Product summary
- 12.18.4. Recent developments
12.19. MRM Proteomics Inc.
- 12.19.1. Company details
- 12.19.2. Financial outlook
- 12.19.3. Product summary
- 12.19.4. Recent developments
12.20. MS Bioworks LLC
- 12.20.1. Company details
- 12.20.2. Financial outlook
- 12.20.3. Product summary
- 12.20.4. Recent developments
12.21. PerkinElmer Inc.
- 12.21.1. Company details
- 12.21.2. Financial outlook
- 12.21.3. Product summary
- 12.21.4. Recent developments
12.22. Poochon Scientific, LLC
- 12.22.1. Company details
- 12.22.2. Financial outlook
- 12.22.3. Product summary
- 12.22.4. Recent developments
12.23. Promega Corporation
- 12.23.1. Company details
- 12.23.2. Financial outlook
- 12.23.3. Product summary
- 12.23.4. Recent developments
12.24. Proteome Factory AG
- 12.24.1. Company details
- 12.24.2. Financial outlook
- 12.24.3. Product summary
- 12.24.4. Recent developments
12.25. QIAGEN Bioinformatics
- 12.25.1. Company details
- 12.25.2. Financial outlook
- 12.25.3. Product summary
- 12.25.4. Recent developments